News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Actelion Ltd. (ALIOF.PK) and Lundbeck Inc. (LUN.CO) Get Positive CHMP Opinions


10/28/2013 7:50:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The latest set of opinions from advisors to the European Medicines Agency has seen two new medicines recommended for approval. The agency's Committee for Human Medicinal Products (CHMP) has issued a positive recommendation on Opsumit (macitentan), Actelion's new treatment for pulmonary arterial hypertension. The drug, which was approved by the US Food and Drug Administration earlier this month, is the follow-up to the Swiss biotech's blockbuster Tracleer (bosentan), which goes off-patent in 2015.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES